論文 2022年

2022年

英文

  1. Kakeya H. Medical mycology seen through a one health approach. Med Mycol J 63:11-15, 2022
  2. Imoto W, Yamada K, Kuwabara G, Shibata W, Sakurai N, Nonose Y, Okada Y, Nakie K, Fujita A, Kakeya H. Impact of Coronavirus disease 2019 on infectious disease treatment and infection control at a tertiary hospital in Japan. J Infect Chemother, 2022, 2022 Jan 26:S1341-321X(22)00020-4.
  3. Sakurai N, Kawaguchi H, Kuwabara G, Imoto W, Shibata W, Yamada K, Nakamura Y, Kakeya H. Body mass index of elderly patients with normal renal function as a determining factor for initial vancomycin regimen designing. Chemotherapy. 2022 Feb 8. doi: 10.1159/000522455.
  4. Takazono T, Mukae H, Izumikawa K, Kakeya H, Ishida T, Hasegawa N, Yokoyama A. Empirical antibiotic usage and bacterial superinfections in patients with COVID-19 in Japan: A nationwide survey by the Japanese Respiratory Society. Respir Investig. 2022 Jan;60(1):154-157.
  5. Ishida T, Seki M, Oishi K, Tateda K, Fujita J, Kadota J, Kawana A, Izumikawa K, Kikuchi T, Ohmagari H, Yamada M, Maruyama T, Takazono T, Miki M, Miyazaki Y, Yamazaki Y, Kakeya H, Ogawa K, Watanabe A. Clinical manifestations of hospitalized influenza patients without risk factors: A prospective multicenter cohort study in Japan via internet surveillance. J Infect Chemother 2022. https://doi.org/10.1016/j.jiac.2022.02.001
  6. Oka K, Matsumoto A, Tetsuka N, Morioka H, Iguchi M, Ishiguro N, Nagamori T, Takahashi S, Saito N, Tokuda K, Igari H, Fujikura Y, Kato H, Kanai S, Kusama F, Iwasaki H, Furuhashi K, Baba H, Nagao M, Nakanishi M, Kasahara K, Kakeya H, Chikumi H, Ohge H, Azuma M, Tauchi H, Shimono N, Hamada Y, Takajo I, Nakata H, Kawamura H, Fujita J; Japan Infection Prevention and Control Conference for National and Public University Hospitals. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. J Glob Antimicrob Res, 29:247-252, 2022. doi: 10.1016/j.jgar.2022.04.004.
  7. Yamaguchi M, Yamairi K, Fujii H, Miki Y, Mamoto T, Yagyu K, Niki M, Kakeya H, Shoji S. A case of allergic bronchopulmonary mycosis due to Schizophyllum commune with elevated serum carcinoembryonic antigen levels. Res Med Case Rep, 2022. https://doi.org/10.1016/j.rmcr.2022.101677
  8. Kuwabara G, Yamada K, Tanaka K, Nozuchi S, Imoto W, Shibata W, Tohda M, Kyoh S, Itoh Y, Hashimoto M, Kakeya H. Muscle Biopsy-proven Drug-induced Microscopic Polyangiitis in a Patient with Tuberculosis. Intern Med. 2023;62(1):129-133. doi: 10.2169/internalmedicine.9599-22.
  9. Imoto W, Yamada K, Kakeya H. Long COVID with intracranial microangiopathy. QJM 2022 Jun 15; hcac139. doi: 10.1093/qjmed/hcac139.
  10. Sakurai N, Kawaguchi H, Abe J, Kuwabara G, Imoto W, Shibata W, Yamada K, Yasui H, Nakamura Y, Kakeya H. Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients. Pharmacotherapy 2022 Sep;42(9):707-715. doi: 10.1002/phar.2719.
  11. Morioka H, Ohge H, Nagao M, Kato H, Kokado R, Yamada K, Yamada T, Shimono N, Nukui Y, Yoshihara S, Sakamaki I, Nosaka K, Kubo Y, Kawamura H, Fujikura Y, Kitaura T, Sunakawa M, Yagi T; Research Group of Japan Infection Prevention and Control Conference for National and Public University Hospitals.　 Appropriateness of surgical antimicrobial prophylaxis in Japanese university hospitals. J Hosp Infect. 2022 Jul 11:S0195-6701(22)00218-3. doi: 10.1016/j.jhin.2022.06.017.
  12. Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Komiya E, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagami-Yamaguchi E, Ohfuji S, Kaneko K, Kaneko A, Kakeya H, Hirota Y. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: a prospective cohort study in Japan. Vaccine, 2022;40:5631-5640.
  13. Kinoshita T, Shinoda M, Nishizaki Y, Shiraki K, Hirai Y, Kichikawa Y, Tsushima K, Sinkai M, Komura N, Yoshida K, Kido Y, Kakeya H, Uemura N, Kadota J. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med, 2022;20:342.
  14. Shibata W, Uchida K, Ozawa D, Imai H, Endo S, Watanabe Y, Kosai K, Kawamoto Y, Uehara H, Sugimoto N, Namikawa H, Mizobata Y, Kanemitsu K, Yano H, Kaku M, Seki M, Yanagihara K, Kakeya H. Clinical Evaluation of Cell-Direct Polymerase Chain Reaction-Based Nucleic Acid Lateral Flow Immunoassay for Rapid Detection of Bacterial Pathogens in Clinically Suspected Sepsis: A Multi-Center Study in Japan. J Microbiol Methods. 2022 Oct;201:106566. doi: 10.1016/j.mimet.2022.106566.
  15. Kohno S, Izumikawa K, Takazono T, Miyazaki T, Yoshida M, Kamei K, Ogawa K, Taniguchi S, Akashi K, Tateda K, Mukae H, Miyazaki Y, Okada F, Kanda Y, Kakeya H, Suzuki J, Kimura SI, Kishida M, Matsuda M, Niki Y. Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. J Infect Chemother. 2023;29(2):163-170. doi: 10.1016/j.jiac.2022.10.010.
  16. Imoto W, Yamada K, Kawai R, Imai T, Kawamoto K, Uji M, Kanda H, Takada M, Ohno Y, Ohtani H, Kono M, Hikiishi A, Eguchi Y Namikawa H, Kawaguchi T, Kakeya H. A cross-sectional, multicenter survey of the prevalence and risk factors for Long COVID. Sci Rep. 2022; 12:22413. doi.org/10.1038/s41598-022-25398-6.
  17. Nakagama Y, Candray K, Kaku N, Komase Y, Rodriguez-Funes MV, Dominguez R, Tsuchida T, Kunishima H, Nagai E, Adachi E, Ngoyi DM, Yamasue M, Komiya K, Hiramatsu K, Uemura N, Sugiura Y, Yasugi M, Yamagishi Y, Mikamo H, Shiraishi S, Izumo T, Nakagama S, Watanabe C, Nitahara Y, Tshibangu-Kabamba E, Kakeya H, Kido Y. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. J Infect Dis. 2023;227(6):780-787. doi: 10.1093/infdis/jiac492.
  18. Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Nakaie K, Nakatsuka Y, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H. The Clinical Evaluation of Third-generation Cephalosporins As Definitive Therapy for Enterobacter spp. and Klebsiella aerogenes Bacteremia. Intern Med. 2023;62(13):1921-1929. doi: 10.2169/internalmedicine.0612-22
  19. Imoto W, Matsumoto S, Suzuki M, Ban N, Horikawa M, Mitani K, Ogawa M, Kakuno S, Shibata W, Niki M, Yamada K, Okada M, Kakeya H. First report of Mycobacterium virginiense-induced synovitis and tenosynovitis of flexor digitorum superficialis and profundus muscles in Japan. J Infect Chemother. 2023;29(4):410-413. doi: 10.1016/j.jiac.2022.12.014.

和文

  1. 掛屋　弘. 緑膿菌感染症（多剤耐性菌を含む）. 今日の治療指針2022. 医学書院 2022, pp221-223.
  2. 掛屋　弘. ムーコル症（接合菌症）pp. I-360-I361, 内科学第12版. 朝倉書店、2022
  3. 掛屋　弘. 特集　肺真菌症の病態・診断・治療　慢性肺アスペルギルス症. 呼吸器内科. 41(3):249-255, 2022
  4. 掛屋　弘. 私の治療　肺真菌症 日本医事新報. 5111(4):40-41, 2022
  5. 掛屋　弘. 特集 感染症から地域と施設を守る　リンクナースの育成と活用　「大阪府における新型コロナウイルス感染対策の振り返り」看護展望 47(6): 10-13, 2022
  6. 柴多　渉, 掛屋　弘. 真菌の分類・命名をめぐる歴史と諸問題. 臨床と微生物. 49(4);057-064, 2022
  7. 山田康一. 呼吸器感染症. 消化器感染症. 肝胆道系感染症.抗菌薬適正使用Q＆A. 多職種で取り組む抗菌薬適正使用. 医薬出版株式会社,2022
  8. 掛屋　弘. COVID-19に対する抗ウイルス薬. 呼吸器内科. 2022;42(2):192-198.
  9. 井本和紀, 掛屋　弘. 肺炎・結核. 糖尿病ケア 2022;19(6):85-87.
  10. 仁木 誠, 井本和紀, 山田康一, 金子幸弘, 掛屋 弘. 血液培養から検出された Clostridium 属およびClostridioides 属の細菌学的検討. 日本嫌気性菌学会雑誌 2022;52(2):66-77.

その他

  1. 掛屋　弘. 医なび 肺マック症. 読売新聞　夕刊（2022.3.29）
  2. 掛屋　弘. 土曜特集　どう見る？新型コロナ繰り返す変異. 公明新聞 夕刊（2022.8.20）
論文 2023年
論文バックナンバーに戻る
論文 2021年